According to Global Business Intelligence, the global epilepsy drugs revenue was worth USD 4.1 billion in 2011. The estimated global market size of epilepsy drugs in 2013 was USD 4.28 billion. With a Compound Annual Growth Rate (CAGR) of 2 percent through 2009-2018, it is expected to clock a turnover of USD 4.73 billion in 2018. The epilepsy drug market accrued revenue worth USD 1.1 billion in 2012. It was estimated to reach to USD 1.16 billion in 2013 with a CAGR of 5 percent throughout 2009-2013. Majority of this share was accounted by Australia, China, India and Japan. India with over 1 billion population is likely to have more than a million patients with epilepsy. According to Times of India, around 14 people per 1,000 population are expected to suffer from epilepsy. Epilepsy is more prevalent among children and young adults and in the rural areas. In India about 95 percent of epileptic patients do not receive any treatment. With a CAGR of 15 percent throughout 2009-2013, the market size of anti-epileptic drugs was estimated at USD 164.93 million in 2013.

1. Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Gyan Research and Analytics (Gyan). While
reasonable care has been taken in its preparation, Gyan makes no representation or warranty, express or implied, as to the accuracy, timeliness or
completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as
statements of opinion and Gyan will not be liable for any loss incurred by users from any use of the publication or contents.
Epilepsy Drug
Market in India:
(2014-2018)

2. Epilepsy Drugs Market in India: (2014-2018)
2 | P a g e
© Gyan Research and Analytics Pvt. Ltd., 2014
Synopsis
According to Global Business Intelligence, the global epilepsy drugs revenue was worth USD 4.1
billion in 2011. The estimated global market size of epilepsy drugs in 2013 was USD 4.28 billion. With
a Compound Annual Growth Rate (CAGR) of 2 percent through 2009-2018, it is expected to clock a
turnover of USD 4.73 billion in 2018. The epilepsy drug market accrued revenue worth USD 1.1
billion in 2012. It was estimated to reach to USD 1.16 billion in 2013 with a CAGR of 5 percent
throughout 2009-2013. Majority of this share was accounted by Australia, China, India and Japan.
India with over 1 billion population is likely to have more than a million patients with epilepsy.
According to Times of India, around 14 people per 1,000 population are expected to suffer from
epilepsy. Epilepsy is more prevalent among children and young adults and in the rural areas. In India
about 95 percent of epileptic patients do not receive any treatment. With a CAGR of 15 percent
throughout 2009-2013, the market size of anti-epileptic drugs was estimated at USD 164.93 million
in 2013.
Since the research and development associated with the innovation of new anti-epileptic drugs are
costly, the rate of innovation in much low in India. The probability of successful innovation of AED is
even less than 10 percent. Moreover, these cases of research process are associated with high
investment with lack of safety and efficacy. Thus, proper monitoring is required in order to bring in
innovative drugs into the market.
Emergence of new anti-epileptic drugs and awareness of the disease among the Indians can serve
better prospects for the market to develop. With companies like Johnson & Johnson,
GlaxoSmithKline, Abbott, Cephalon and many others operating in the country, the market for the
anti-epileptic drugs is expected to grow in future and reach revenue worth USD 208.69 million in
2019.

3. Epilepsy Drugs Market in India: (2014-2018)
3 | P a g e
© Gyan Research and Analytics Pvt. Ltd., 2014
Table of Content
1. Global Epilepsy Drugs Market
2. Epilepsy Drugs Market in Asia-Pacific (APAC)
3. Epilepsy Drug Market in India
4. Major Trends
4.1 High Cost of Treatment
4.2 Large Number of Patients devoid of Treatment
4.3 High Rate of Epilepsy Prevalence in Some Cities
4.4 High Number of Patients
4.5 Pregnancy and Epilepsy
4.6 Epilepsy and Educational Problem
4.7 Introduction of New Smartphone Apps to Detect Epilepsy
4.8 Economic Failure of Anti- Epileptic Drugs
5. Outlook

4. Epilepsy Drugs Market in India: (2014-2018)
4 | P a g e
© Gyan Research and Analytics Pvt. Ltd., 2014
GYAN RESEARCH AND ANALYTICS PVT. LTD.
Corporate Office:
LG 37-38, Ansal Fortune
Arcade, Sector-18,
Noida- 201 301
Delhi NCR, INDIA
Phone: +91-120-4235181
Regd. Office:
298-A, Pocket 2
Mayur Vihar Phase -1
Delhi 110 091, INDIA
Central Delivery Centre:
BD-9, Sector-1,
Salt Lake City
Kolkata- 700 064, INDIA
Phone: +91-33-40060084
E-mail: reports@gyananalytics.com
Website: www.gyananalytics.com